EGFR and pancreatic neoplasm: In light of elevated p-ERK levels in mutant PLXNA1 overexpressing cells, we subjected both SB.06 and SB.07 cells to treatment with the EGFR inhibitor erlotinib and the dual PI3K/mTOR inhibitor BEZ235 and measured an increased resistance in SB.06 cells compared to SB.07 and other wild type PLXNA1 harboring pancreas cancer cells.